FFA
OVID icon

Frazier Financial Advisors’s Ovid Therapeutics OVID Stock Holding History

Frazier Financial Advisors’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10
Closed -$4 – 652
2025
Q1 		$4 Hold
10
– – ﹤0.01% 607
2024
Q4 		$10 Hold
10
– – ﹤0.01% 641
2024
Q3 		$12 Hold
10
– – ﹤0.01% 836
2024
Q2 		$8 Hold
10
– – ﹤0.01% 986
2024
Q1 		$31 Buy
+10
New +$33 ﹤0.01% 910

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Frazier Financial Advisors's OVID Position: Q2 2025 in Review

Frazier Financial Advisors sold out of Ovid Therapeutics (OVID) in Q2 2025, closing a stake of 10 shares — an estimated $4 sold.

Frazier Financial Advisors first reported a position in OVID in Q1 2024 and held it in 5 quarters. The position peaked at $31 in Q1 2024. 71 funds tracked by Wall St. Rank hold OVID as of Q2 2025.

  • Frazier Financial Advisors reported no remaining Ovid Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Frazier Financial Advisors sold 10 Ovid Therapeutics shares in Q2 2025, an estimated $4.
  • Frazier Financial Advisors first reported a position in Ovid Therapeutics in Q1 2024 and held it in 5 quarters.
  • Frazier Financial Advisors's Ovid Therapeutics position peaked at $31 in Q1 2024.
  • 71 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2025.

Based on Frazier Financial Advisors's 13F filing for Q2 2025, filed 28 Jul 2025.